With 14 biopharmaceutical products in the market, Roche is the largest biopharmaceuticals company in the world. Its in-vitro diagnostics has also been successful in innovating new ways to address the need for cancer-fighting drugs.
The year 2011 was extra special for Roche because of the key approvals the company gained for some anti-cancer drugs and other new medicines against multiple sclerosis. For the third time in a row, Roche leads the pharmaceuticals sector in the Dow Jones Sustainability Index.
To express its commitment to innovation, Roche is spending more than 8 billion Swiss francs for R&D to continue its firm hold in developing drugs. Its R&D efforts are also geared towards developing personalized drugs to cure asthma, Hepatitis C, depression, schizophrenia and Alzheimer’s disease.
At present, Roche has over 200 medicine discovery projects.